Neurodegenerative diseases (NDDs) consist of a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, hereditary optic neuropathies, and many others. NDDs affected over 55 million people worldwide in 2020, and the number could double in the next 20 years. In the case of Alzheimer's disease and Parkinson's disease, the two most common NDDs, over 6.2 million and 1 million people currently in the United States may be affected, respectively.
Tremendous progress was made in the past decade in understanding the pathophysiology of NDDs using biomarkers, including the tau protein and amyloid-beta peptide, and mutations, such as APP, PSEN1, and PSEN2. However, it is far from clear to elucidate the cellular and molecular mechanisms underlying NDDs, and it is still in its infancy to comprehensively map the etiology, pathogenesis, and prognosis of NDDs. Such a gap in knowledge calls for investigations in novel humoral, genetic, and imaging biomarkers of NDDs for early detection, diagnosis, prognosis, and prediction, as well as next-generation sequencing studies identifying gene candidates altered in NDDs.
This Research Topic aims to collect recent progress in basic and clinical research studies profiling the molecular pathology of NDDs, investigating etiology and pathogenesis, and identifying humoral, genetic, and imaging biomarkers for clinical settings for NDDs detection, diagnosis, prognosis, and prediction. We are also looking for studies or computational methods investigating NDDs using high-throughput approaches, such as next-generation sequencing, single-cell omics, digital pathology, functional imaging, and others.
This Research Topic welcomes submissions of the following article types:
- Original Research
- Brief Research Report
- Clinical Trial
- Review
The scope of the Research Topic includes but is not limited to:
- Early detection and identification of novel biomarkers for NDDs
- Body fluid biomarkers for NDDs
- Genetic biomarkers for NDDs
- Epigenetic biomarkers for NDDs
- Non-coding RNA biomarkers for NDDs
- Next-generation sequencing, in particular, single-cell omics studies of NDDs pathology and pathogenesis
- Genome-wide association studies of NDDs
- Functional imaging studies
- Digital pathology studies, including computational approaches in NDDs identification or classification or other early prediction or risk evaluation approaches
Neurodegenerative diseases (NDDs) consist of a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, hereditary optic neuropathies, and many others. NDDs affected over 55 million people worldwide in 2020, and the number could double in the next 20 years. In the case of Alzheimer's disease and Parkinson's disease, the two most common NDDs, over 6.2 million and 1 million people currently in the United States may be affected, respectively.
Tremendous progress was made in the past decade in understanding the pathophysiology of NDDs using biomarkers, including the tau protein and amyloid-beta peptide, and mutations, such as APP, PSEN1, and PSEN2. However, it is far from clear to elucidate the cellular and molecular mechanisms underlying NDDs, and it is still in its infancy to comprehensively map the etiology, pathogenesis, and prognosis of NDDs. Such a gap in knowledge calls for investigations in novel humoral, genetic, and imaging biomarkers of NDDs for early detection, diagnosis, prognosis, and prediction, as well as next-generation sequencing studies identifying gene candidates altered in NDDs.
This Research Topic aims to collect recent progress in basic and clinical research studies profiling the molecular pathology of NDDs, investigating etiology and pathogenesis, and identifying humoral, genetic, and imaging biomarkers for clinical settings for NDDs detection, diagnosis, prognosis, and prediction. We are also looking for studies or computational methods investigating NDDs using high-throughput approaches, such as next-generation sequencing, single-cell omics, digital pathology, functional imaging, and others.
This Research Topic welcomes submissions of the following article types:
- Original Research
- Brief Research Report
- Clinical Trial
- Review
The scope of the Research Topic includes but is not limited to:
- Early detection and identification of novel biomarkers for NDDs
- Body fluid biomarkers for NDDs
- Genetic biomarkers for NDDs
- Epigenetic biomarkers for NDDs
- Non-coding RNA biomarkers for NDDs
- Next-generation sequencing, in particular, single-cell omics studies of NDDs pathology and pathogenesis
- Genome-wide association studies of NDDs
- Functional imaging studies
- Digital pathology studies, including computational approaches in NDDs identification or classification or other early prediction or risk evaluation approaches
